Skip to main content

Table 2 Key response results

From: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

Parameter HL patients ALCL patients
  (N = 20) (N = 8)
Objective response rate (CR + PR) 12 (60) 7 (88)
Best clinical responsea   
Complete remission 6 (30) 5 (63)
Partial remission 6 (30) 2 (25)
Stable disease 4 (20) 0
Progressive disease 4 (20) 1 (13)
95% CI for ORRb 36.1, 80.9 47.3, 99.7
95% CI for CR rateb 11.9, 54.3 24.5, 91.5
Duration of objective response for patients with OR, monthsc 12 (60) 7 (88)
Median (95% CI)d 9.2 (2.1, -) 12.3 (6.6, -)
Duration of response for patients with CR, monthsc 6 (30) 5 (63)
Median (95% CI)d 9.4 (1.7, 14.2) 12.9 (7.4, -)
Progression-free survival, monthse   
Median (95% CI)d 9.9 (3.4, 13.4) 12.9 (1.4, 18.5)
Overall survival, monthse   
Median (95% CI)d - (11.4, -) - (3.3, -)
  1. Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.
  2. aBest response (according to Cheson 2007) prior to the start of any new antitumor treatment, exclusive of stem cell transplant.
  3. bTwo-sided 95% exact confidence interval (CI), computed using the Clopper-Pearson method (1934).
  4. cDuration of response is calculated from the earliest occurrence of either complete or partial remission.
  5. dComputed using the log-log transformation method of Collett (1994).
  6. e As estimated using Kaplan-Meier methods.